Persistent Inflammation Predicts Hospitalization After CPAP: A 12-Month Cohort Study in Obstructive Sleep Apnea
International Journal of Pharmaceutical Quality Assurance · 11.03.2026 · 17 (03)
DOI: 10.25258/ijpqa.17.3.7 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 11.03.2026. Verfasst von Lokendra Dave und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Obstructive sleep apnea (OSA) is associated with systemic inflammation and increased cardiopulmonary morbidity. Although continuous positive airway pressure (CPAP) is the standard therapy, its impact on inflammatory biomarkers and their relationship with clinical outcomes such as hospitalization remains incompletely understood. Aim and Objectives: This study evaluated changes in C-reactive protein (CRP) and body mass index (BMI) over 12 months of CPAP therapy and examined whether baseline or persistent inflammation predicts dyspnea-related hospitalization. Materials and Methods: In this prospective cohort study, 166 adults with polysomnography-confirmed OSA initiating CPAP were enrolled. After exclusion of deaths and 76 participants lost to follow-up or non-adherent to CPAP, 90 patients completed 12-month evaluation. Baseline demographics, comorbidities, CRP, and BMI were recorded and reassessed at 12 months. The primary outcome was change in CRP; secondary outcomes included BMI change and time to first hospitalization for dyspnea. Analyses included paired tests, Chi-square tests, Cox proportional hazards models, Kaplan–Meier curves, and Fine-Gray competing-risk regression.
Results
CRP decreased significantly after 12 months of CPAP (median 4.1 to 2.6 mg/L, p < 0.001), whereas BMI showed no significant change (31.6 to 31.5 kg/m², p = 0.12). Forty-one patients (45.6%) required dyspnearelated hospitalization, with 78% of events occurring after 8 months. Hospitalized patients had higher baseline CRP, higher 12-month CRP, and worsening CRP over time. In univariate Cox analysis, age, smoking, drinking, hypertension, baseline CRP, post-therapy CRP, and persistently high CRP were associated with increased hospitalization risk. In multivariate analysis, baseline CRP (HR 1.18), post-therapy CRP (HR 1.23), and persistently elevated CRP (HR 1.92) remained independent predictors, along with age, drinking history, and hypertension. Fine-Gray competing-risk models confirmed that CRP—but not BMI—was consistently associated with higher subdistribution hazard for dyspnea-related hospitalization.
Conclusions
Twelve months of CPAP therapy significantly reduced systemic inflammation but did not alter BMI. Persistently elevated or rising CRP was strongly associated with increased risk of dyspnea-related hospitalization, while BMI showed limited prognostic value. These findings support CRP as a clinically relevant biomarker for risk stratification in CPAP-treated OSA and highlight the need for continued monitoring of inflammatory status and comorbid conditions to identify patients at elevated risk of clinical deterioration.
Zitieren
APA
Dave, L., Sharma, P., Gupta, V., Kurmi, V. K., Dandekar, P. G., & Mishra, V. K. (2026). Persistent Inflammation Predicts Hospitalization After CPAP: A 12-Month Cohort Study in Obstructive Sleep Apnea. International Journal of Pharmaceutical Quality Assurance, 17(03). https://doi.org/10.25258/ijpqa.17.3.7
Vancouver
Dave L, Sharma P, Gupta V, Kurmi VK, Dandekar PG, Mishra VK. Persistent Inflammation Predicts Hospitalization After CPAP: A 12-Month Cohort Study in Obstructive Sleep Apnea. International Journal of Pharmaceutical Quality Assurance. 2026;17(03). doi:10.25258/ijpqa.17.3.7
BibTeX
@article{Dave2026,
author = {Dave, Lokendra and Sharma, Parag and Gupta, Vishwas and Kurmi, Vinod Kumar and Dandekar, Pravin Gulab and Mishra, Vikas Kumar},
title = {Persistent Inflammation Predicts Hospitalization After CPAP: A 12-Month Cohort Study in Obstructive Sleep Apnea},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {03},
doi = {10.25258/ijpqa.17.3.7}
}
EUVIMED